ArticleCell reports. Medicine2025

Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer.

Subhamoy Chakraborty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.